NCT01610869 - Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

January 11, 2018

Study Completion Date

January 11, 2018

Conditions

Ovarian CancerFallopian Tube Cancer

Interventions

DRUG

BIBF 1120

Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.

Trial Locations (16)

Kent Oncology Centre, Maidstone

Beatson West of Scotland Cancer Centre, Glasgow

Velindre Hospital, Cardiff

Royal United Hospital, Bath

Addenbrookes Hospital, Cambridge

Royal Derby Hospital, Derby

Royal Surrey County Hospital, Guildford

St James's University Hospital, Leeds

Clatterbridge Centre for Oncology, Liverpool

Mount Vernon Hospital, London

Royal Marsden Hospital, London

St Bartholomew's Hospital, London

University College London Hospital (UCLH), London

Christie Hospital, Manchester

Churchill Hospital, Oxford

Wexham Park Hospital, Slough